Effects of a cannabinoid1 receptor antagonist and serotonin 2c receptor agonist alone and in combination on motivation for palatable food: A dose-addition analysis study in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 2, 2008, Pages 567-576

  Ward, Sara Jane ^a,b   Lefever, Timothy W ^a   Jackson, Cavario ^a   Tallarida, Ronald J ^a   Walker, Ellen A ^a  

^a TEMPLE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ENSURE; RIMONABANT; 1-(3-CHLOROPHENYL)PIPERAZINE; CANNABINOID 1 RECEPTOR; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; FEEDING BEHAVIOR; FOOD; FOOD INTAKE; MALE; MOTIVATION; MOUSE; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; ANIMAL; DRUG ANTAGONISM; PHYSIOLOGY;

ANIMALS; DRUG SYNERGISM; FEEDING BEHAVIOR; MALE; MICE; PIPERAZINES; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS;

EID: 42449164739     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.131771     Document Type: Article

References (40)

1. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, and Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132:104-106.
2. Berry EM and Mechoulam R (2002) Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 95:185-190.
3. Bray GA and Greenway FL (2007) Pharmacological treatment of the overweight patient. Pharmacol Rev 59:151-184.
4. Cohen C, Perrault G, Voltz C, Steinberg R, and Soubrié P (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451-463.
5. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, and Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113-PL117.
6. Cowen PJ, Sargent PA, Williams C, Goodall EM, and Orlikov AB (1995) Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women. Hum Psychopharmacol 10:385-391.
7. Curzon G, Gibson EL, and Oluyomi AO (1997) Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 18:21-25.
8. Dunlop J, Marquis KL, Lim HK, Leung L, Kao J, Cheesman C, and Rosenzweig-Lipson S (2006) Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909: therapeutic potential in multiple indications. CNS Drug Rev 12:167-177.
9. Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, Trabace L, and Ciccocioppo R (2006) Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology 183:394-403.
10. Finer N, Craddock D, Lavielle R, and Keen H (1987) Prolonged weight loss with dexfenfluramine treatment in obese patients. Diabetes Metab 13:598-602.
11. Fischer BD and Dykstra LA (2006) Interactions between an N-methyl-D-aspartate antagonist and low-efficacy opioid receptor agonists in assays of schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther 318:1300-1306.
12. Grottick AJ, Fletcher PJ, and Higgins GA (2000) Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior. J Pharmacol Exp Ther 295:1183-1191.
13. Halford JC, Harrold JA, Boyland EJ, Lawton CL, and Blundell JE (2007) Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67:27-55.
14. Hewitt KN, Lee MD, Dourish CT, and Clifton PG (2002) Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 71:691-700.
15. Hodos W and Kalman G (1963) Effects of increment size and reinforcer volume on progressive ratio performance. J Exp Anal Behav 6:387-392.
16. Järbe TU, Andrzejewski ME, and DiPatrizio NV (2002) Interactions between the CB1 receptor agonist delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73:911-919.
17. Kelsey JE and Calabro S (2007) Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats. Psychopharmacology, in press.
18. Moranta D, Esteban S, and García-Sevilla JA (2004) Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 369:516-524.
19. Poncelet M, Maruani J, Calassi R, and Soubrie P (2003) Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 343:216-218.
20. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, and Soubrie P (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648.
21. Richardson NR and Roberts DC (1991) Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci 49:833-840.
22. Roberts DC, Loh EA, Baker GB, and Vickers G (1994) Lesions of central serotonin systems affect responding on a progressive ratio schedule reinforced either by intravenous cocaine or by food. Pharmacol Biochem Behav 49:177-182.
23. Rotzinger S, Fang J, Coutts RT, and Baker GB (1998) Human CYP2D6 and metabolism of mchlorophenylpiperazine. Biol Psychiatry 44:1185-1191.
24. Rowland NE, Mukherjee M, and Robertson K (2001) Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 159:111-116.
25. Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, and Garattini S (1979) Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch Pharmacol 308:159-163.
26. Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, and Spanagel R (2004) Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology 176:223-232.
27. Solinas M, Panlilio LV, Antoniou K, Pappas LA, and Goldberg SR (2003) The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306:93-102.
28. Soria G, Mendizábal V, Touriño C, Robledo P, Ledent C, Parmentier M, Maldonado R, and Valverde O (2005) Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmology 30:1670-1680.
29. Stafford D, LeSage MG, and Glowa JR (1998) Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology 139:169-184.
30. Stiedl O, Misane I, Koch M, Pattij T, Meyer M, and Ogren SO (2007) Activation of the brain 5-HT2C receptors causes hypolocomotion without anxiogenic-like cardiovascular adjustments in mice. Neuropharmacology 52:949-957.
31. Tallarida RJ (2000) Drug Synergism and Dose-effect Data Analysis, Chapman & Hall/CRC, Boca Raton.
32. Tallarida RJ (2006) An overview of drug combinations with isobolograms. J Pharmacol Exp Ther 319:1-7.
33. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, and Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374:542-546.
34. Traynor K (2007) Panel advises against rimonabant approval. Am J Health Syst Pharm 64:1460-1461.
35. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, and Nomikos GG (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544-553.
36. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, and Nomikos GG (2001) The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 426:R3-R4.
37. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, and Rossner S; RIO Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397.
38. Ward SJ and Dykstra LA (2005) The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 16:381-388.
39. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, and Martin BR (2005) CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145:293-300.
40. Wolff MC and Leander JD (2000) A comparison of the behavioural effects of 5-HT2A and 5-HT2C receptor agonists in the pigeon. Behav Pharmacol 11:355-364.